FrancineMarieFossMD

Oncology • New Haven, CT

Cutaneous Lymphoma, Hematologic Oncology

Professor of Medicine, Yale University School of Medicine

Join to view full profile

Dr. Foss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Foss' full profile

Already have an account?

Office
800 Howard Ave
Yale Physicians Building
New Haven, CT 06519
Phone+1 203-785-7005

Fax+1 203-785-3788

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
Brigham and Women's HospitalResidency, Internal Medicine, 1982 - 1985
University of Massachusetts Medical SchoolClass of 1982
National Institutes of Health Clinical CenterFellowship, Medical Oncology

Certifications & Licensure

FL State Medical License 2024 - Present
NY State Medical License 2024 - 2026
CT State Medical License 2004 - 2025
MA State Medical License 1985 - 2025
MD State Medical License 1986 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Join now to see all

Clinical Trials

Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma Start of enrollment: 2005 Nov 09
Terminated
Phase 2
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Start of enrollment: 2004 Mar 14
Completed
Phase 2
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Start of enrollment: 2001 May 01
Completed
Phase 4
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma Start of enrollment: 2005 Nov 01
Completed
Phase 2
Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Start of enrollment: 2005 Oct 01
Completed
Phase 1
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Start of enrollment: 2006 Jul 01
Completed
Phase 2
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma Start of enrollment: 2007 Jul 01
Completed
Phase 2
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas Start of enrollment: 2009 Jan 01
Terminated
Phase 1, Phase 2
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry Start of enrollment: 2010 Feb 01
Completed
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Start of enrollment: 2009 Oct 01
Completed
Phase 1
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Start of enrollment: 2012 Nov 01
Completed
Phase 3
An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) Start of enrollment: 2012 Oct 01
Terminated
Phase 1
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Start of enrollment: 2015 Jun 11
Active, not recruiting
Phase 2
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas Start of enrollment: 2015 Jul 01
Active, not recruiting
Phase 1, Phase 2
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides Start of enrollment: 2019 Apr 02
Terminated
Phase 2
Study Of Intratumoral G100 In Cutaneous T Cell Lymphoma Start of enrollment: 2019 Jun 01
Withdrawn
Phase 2
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma. Start of enrollment: 2018 Oct 14
Recruiting
Join now to see all

Publications & Presentations

PubMed

6 citations
Clinical Experience: Practical Management of Five Patients With Cutaneous T-Cell Lymphoma (CTCL)-Related Symptoms
Reinhard Dummer, Francine M. Foss, Brigitte Dréno, Martine Bagot
Seminars in Oncology. 2006-02-01
487 citations
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol
Journal of Clinical Oncology. 2012-02-20
251 citations
Peripheral T-cell lymphoma
Francine M. Foss, Pier Luigi Zinzani, Julie M. Vose, Randy D. Gascoyne, Steven T. Rosen
Blood. 2011-06-23

Journal Articles

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 Study
Michael S Khodadoust, Pierluigi Porcu, Francine Foss, Andrei R Shustov, Satish Shanbhag, Lubomir Sokol, Steven M Horwitz, Elad Sharon, European Journal of Cancer

Abstracts/Posters

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Francine M. Foss, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ph 1 study of MRG-106, an inhibitor of miR-155, in CTCL.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Emerging Role of Novel Therapies in Cutaneous T-Cell Lymphoma
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Diagnosis & Treatment of Pregnancy-Related Cancers in Women: Pregnancy, Fertility & Beyond
Yale CME, New Haven, Connecticut - 6/8/2012
Join now to see all

Authored Content

Pembrolizumab in Mycosis Fungoides and Sézary Syndrome: Updated Results of the CITN Multicenter Phase 2 StudyAugust 2018

Press Mentions

$FDA Approves Denileukin Diftitox-cxdl for Relapsed/Refractory Cutaneous T-Cell Lymphoma$
FDA Approves Denileukin Diftitox-cxdl for Relapsed/Refractory Cutaneous T-Cell LymphomaAugust 12th, 2024
Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic MalignanciesFebruary 4th, 2020
T-cell Lymphoma Registries: What Have We Learned?September 11th, 2019
Join now to see all

Grant Support

Intravenous Bcx34 In Refractory T Cell &Non-T Cell MalignanciesNational Center For Research Resources2000–2002
IL2 With Photopheresis For Cutaneous T Cell LymphomaNational Center For Research Resources2000–2002
Docetaxel &Trastuzumab In HER2 Expressing Metastatic Breast CancerNational Center For Research Resources2000–2002
Cordycepin + Deoxycoformycin In Refractory Td-T-Positive LeukemiaNational Center For Research Resources2000–2002
94010 Phase I Study Of Oral BCX 34 In Patients With T Cell MalignanciesNational Center For Research Resources1999–2000
Biology And Signal Transduction Of The IL-7 Receptor ProgramNational Cancer Institute1998–2000
Biology And Signal Transduction Of The IL-7 Receptor ProgramNational Cancer Institute1996–1997